Last updated 16 days ago
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)
420 patients around the world
Available in Argentina, United States
Sanofi
1Research sites
420Patients around the world
This study is for people with
Dermatitis
Atopic dermatitis
Requirements for the patient
From 12 Years
All Gender
Medical requirements
SponsorSanofi
Conditions
Atopic dermatitis
Requirements
From 12 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT06181435
